This article was originally published in The Gray Sheet
ABCD trial comparing Cambridge Heart's Heartwave microvolt T-wave alternans (MTWA) system to standard invasive electrophysiology tests for sudden cardiac death risk completes enrollment, sponsor St. Jude Medical announces Sept. 13. The 540-patient trial began in 2001. St. Jude is sponsoring the trial because "the availability of a proven, non-invasive test for this at-risk group may help more patients receive life-saving implantable cardioverter defibrillator therapy," St. Jude VP-Cardiac Rhythm Management Regulatory Affairs Eric Fain explains in a release. Medtronic offers a similar justification for its MASTER trial of the Heartwave system (1"The Gray Sheet" July 14, 2003, p. 32)...
You may also be interested in...
Medtronic is sponsoring a registry to help determine whether microvolt T-wave alternans (MTWA) testing can identify post-MI patients with a left-ventricular ejection fraction (LVEF) of 30%-40% who are most likely to benefit from an ICD
Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.
While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.